In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?
Executive Summary
MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts tell the Pink Sheet.
You may also be interested in...
FDA To Use New Discipline Review Letters In Communicating ANDA Deficiencies To Generic Drugmakers
FDA will be issuing discipline review letters and information request letters to generic drug applicants to communicate shortcomings in ANDAs. Under GDUFA II, the US agency agreed to send out these letters at the mid-point of the review clock.
US FDA's Benefit/Risk Framework Gets High Marks But Could Be Improved
Agency summaries contained in reviews of novel drugs and biologics are useful and informative but difficult to find, and their use should be expanded to other types of applications, industry sponsors and other external stakeholders say.
FDA Exploring Whether Public Shaming Can Stop REMS Abuses
Commissioner Gottlieb says agency is considering publicizing letters it has written to brand companies indicating it would not violate a REMS to sell a generic company samples for testing.